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Hygromycin B was encapsulated in reconstituted Sendai viral envelopes containing only the fusion (F) protein (F-virosomes). Incubation of loaded 
F-virosomes with cultured HepG2 cells resulted in fusion mediated elivery of hygromycin B to the cell cytoplasm, as was inferred from inhibition 
of DNA synthesis. Binding of the F-virosomes to HepG2 cells was mediated by the interaction of terminal f -galactose residues of fusion protein 
with asialoglycoprotein receptor on HepG2 cells, subsequently leading to fusion between the two membranes. The cytotoxic effect of hygromycin 
B enclosed in F-virosomes was comparable with that of F, HN-virosomes containing both hemagglutinin-neuraminidase (HN) and F protein and 
F, HNred-virosomes containing HN whose disulfide bonds were irreversibly reduced (HNrJ.  Hygromycin B loaded fusogenic liposomes were 
prepared by coreconstituting the viral envelope containing only fusion protein with exogenous lipids. These fusogenic liposomes were found to 
be more active than F-virosomes at the same fusion protein concentrations. 
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1. INTRODUCTION 
A major problem in the delivery of drugs and other 
macromolecules into the cells is crossing the permeabil- 
ity barrier imposed by the plasma membrane. Numer- 
ous carriers have been employed in the search for an 
effective delivery system that may allow the transfer of 
their contents into the cytoplasm of specific cells [1,2]. 
In the last few years, closed lipid bilayer vesicles (li- 
posomes) have been extensively used as biological carri- 
ers for introducing biologically active molecules into 
living cells. It appears, however, that liposomes, like 
other particulate matter, are taken up by endocytosis 
and hence do not efficiently introduce their contents 
into the cytoplasm [3]. 
One of the most promising approaches for this pur- 
pose involves the use of reconstituted Sendai viral enve- 
lopes (RSVE). Fusion of loaded RSVE is promoted by 
the viral envelope glycoproteins, which results in micro- 
injection of RSVE contents into the cell cytoplasm [1]. 
Binding of RSVE to cell membrane receptors is medi- 
ated by the viral HN glycoprotein, whereas for the in- 
duction of envelope cell fusion the F protein is essential 
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[1]. During recent years efforts have been made to con- 
struct a targeted RSVE. It has been shown that specific 
antibodies or ligands against cell surface antigens or 
receptors can substitute for the viral binding protein to 
mediate functional binding between the viral envelopes 
and cell membranes [1]. We have recently shown that 
HN protein is not essential for mediating the viral fu- 
sion process [4]. A Sendai mutant deficient in HN pro- 
tein (ts271) has been shown to infect HepG2 cells in 
culture [5]. F is a glycoprotein and contains terminal 
galactose moieties [6] which can specifically recognise 
asialoglycoprotein receptor on the membrane of HepG2 
cells [4,5]. 
In the present work, we have entrapped hygromycin 
B (an aminoglycoside antibiotic active against both 
prokaryotic and eukaryotic ells) within HN depleted 
RSVE (F-virosomes). We show that these loaded F- 
virosomes can effectively fuse with HepG2 cell mem- 
branes and microinject he encapsulated antibiotic in 
the cell cytoplasm. We further show the enhancement 
in the biological activity of hygromycin B when en- 
trapped in fusogenic liposomes containing only the F 
protein of Sendai virus. 
2. MATERIALS AND METHODS 
2.1. Materials" 
Hygromycin B, DTT, WGA and cholesterol were purchased from 
Sigma Chemical Co., USA. Egg phosphatidylcholine was obtained 
from Avanti Polar Lipids, USA. Rabbit reticulocyte lysate was pro- 
cured from Promega Corp., USA. [~4C]Phenylalanine and [3H]thymid- 
ine were from NEN Research Laboratories, USA. Poly(U) was ob- 
tained from Boehringer Mannheim, Germany. Triton X-100 was 
Published by Elsevier Science Publishers B. 14 183 
Volume 326, number  1,2,3 FEBS LETTERS July 1993 
available from Aldrich, USA. Bio-Beads (SM-2) was purchased from 
Bio-Rad, USA. Exoglycosidase (M. mercenaria, hard-shelled clam) 
was a kind gift from Prof. Subhash C. Basu, Notre Dame, IN, USA. 
All other reagents used were of analytical grade. 
2.2. Virus 
Sendai Virus was isolated and its activity was determined as previ- 
ously described [7]. 
2.3. Cells" 
HepG2 cells (human hepatoblastoma cell line from ATCC, USA) 
were grown in monolayers at 37°C, 5% CO2 in D-MEM (Gibco, USA) 
containing 4 mM L-glutamine, 25 mM HEPES, l l0 mg/l sodium 
pyruvate, 10% fetal bovine serum, 100 units/ml penicillin and 100 
~g/ml streptomycin sulfate in 75 cm 2 plastic bottles (Nunc, USA). 
2.4. Construction of loaded virosomes and fusogenic liposomes 
F-Virosomes were prepared following the method of Tomasi and 
Loyter [8] with modifications [4]. Triton X-100 solubilised fraction of 
the virus was mixed with hygromycin B (0.25 M final concentration 
in buffer containing 10 mM Tris-HCl, 150 mM NaCI, 2 mM Ca 2+, 2 
mM Mg 2+, pH 7.4) and reconstituted by stepwise addition of SM-2 
Biobeads as described earlier [4]. This resulted in the formation of 
hygromycin B loaded reconstituted Sendai viral envelopes containing 
only F protein. The unentrapped hygromycin B was removed by 
extensive dialysis against he same buffer followed by centrifugation 
at 100,000 x g for 1 h. Loaded F, HN-virosomes were prepared by 
directly solubilising Sendai virus (20 mg protein) with 40 mg Triton 
X-100 and then treated as above. F, HNred-virosomes with entrapped 
hygromycin B were prepared by treating F, HN-virosomes with 3 mM 
DTT at 37°C for 2 h as described earlier [4]. Fusogenicity of these 
vesicles was measured by their ability to cause hemolysis in the pres- 
ence of wheat germ agglutinin (WGA) [4]. The protein in loaded F-, 
F, HN-, F, HNrea-virosomes and fusogenic liposomes was estimated by 
the method of Markwell et al. [9]. Stability was checked in terms of 
leakage of hygromycin B from these virosomes. Heat treated viro- 
somes were prepared by incubating the virosomes at 56°C for 20 min 
[10]. Degalactosylated virosomes were prepared by treating F-viro- 
somes with clam exoglycosidase following the protocol described by 
Ghosh et al. [11]. Blank virosomes were prepared by reconstituting 
Triton X-100 solubilised fraction in the absence of hygromycin B. 
Fusogenic liposomes (large unilamellar) were prepared following 
the method of Ozawa and Asano [12] with minor modifications. In 
brief, Triton solubilised extract (as described above) was added to a 
film of egg phosphatidylcholin e (PC) (5 ~tmol) and cholesterol (5 
/~mol) (made under N 2 gas) and incubated for 1 h at 20°C with gentle 
rocking. The remaining steps were the same as for the preparation of 
F-virosomes. Activity of fusogenic liposomes was also checked by 
hemolysis of mouse RBC in the presence of WGA [4]. 
The loaded virosomes and liposomes were lysed with Triton X-100 
(0.1%, v/v) and the entrapped hygromycin B was measured by its 
ability to inhibit poly(U)-directed polyphenylalanine synthesis using 
rabbit reticulocyte lysate translation system [13]. The standard curve 
with free hygromycin B was prepared at known concentrations. Intact 
loaded virosomes were also used in this assay as a control to eliminate 
the contribution of surface adsorbed hygromycin B, if any. The effect 
of Txl00 on the in vitro translation was also checked. 
2.5. Fusion mediated microinjection fhygromycin B in HepG2 cells by 
virosomes and fusogenic liposomes 
Interaction of various virosomes containing hygromycin B with 
HepG2 cells was determined by following the inhibition of DNA 
synthesis [14]. Cells were placed in 24-well tissue culture plates at 
2 x 105 cells per well in 2 ml culture medium and allowed to grow for 
24 h in a CO2 incubator. The monolayer cultures were washed twice 
with 2 ml medium with and without serum and incubated with differ- 
ent concentrations ofvirosomal hygromycin B for 18 h at 37°C in 5% 
CO2. The cells were then washed with 2 ml D-PBS twice and were 
cultured with [3H]thymidine (0.2/~Ci) for 6 h. DNA synthesis was 
followed by measuring [3H]thymidine incorporation into cellular 
DNA. Kinetics of cytotoxicity of hygromycin B entrapped in various 
virosome preparations was checked on HepG2 cells by incubating cells 
with fixed amount of virosomes for various time periods followed by 
[3H]thymidine addition. Loaded heat-treated virosomes, trypsinized 
virosomes [1] and black virosomes together with free hygromycin B
were used as controls. After incubation with [3H]thymidine, cells were 
fixed with 5% chilled TCA. Fixed cells were finally dissolved in 0.5 N 
NaOH and the radioactivity associated was measured by liquid scintil- 
lation counter as described by Stubblefield et al. [14]. Specific interac- 
tion between the terminal galactose moiety of F protein and ASGP-R 
on the membrane of HepG2 cells was checked by determining the 
cytotoxicity of hygromycin B encapsulated in degalactosylated F- 
virosomes. 
Cytotoxicity of loaded F-virosomes and fusogenic liposomes was 
compared by incubating these vesicles with HepG2 cells at 37°C for 
12 h and determining the inhibition of DNA synthesis caused by each 
of them as described above. 
3. RESULTS 
3.1. Characterization o f  loaded fusogenic virosomes and 
liposomes 
Vesicle preparat ions  were checked for  the pur i ty  o f  
the enve lope  g lycoprote in  based  on  SDS-PAGE ana ly -  
sis as descr ibed ear l ier  [4]. Hygromyc in  B encapsu la ted  
in tbe vesicles was measured  by its abi l i ty  to inh ib i t  
po ly (U) -d i rec ted  po lypheny la lan ine  synthesis .  The  en- 
t rapment  was ca lcu la ted  as/~g hygromyc in  B assoc ia ted  
per /~g o f  F p ro te in  in vesicles (Table  I). The  rat io  o f  F 
to HN in F, HN-v i rosomes  and  F, HNrca-v i rosomes was 
found to be l : l  (w:w) in all p reparat ions  [4]. As  com-  
pared  to F -v i rosomes  and  F, HN-v i rosomes ,  fusogen ic  
l iposomes  were found to enclose about  10-fold more  o f  
hygromyc in  B (Table I). F-,  F, HN- ,  F, HNrcd-, and  
dega lac tosy la ted  v i rosomes  and  fusogen ic  l iposomes  
were found to be act ive in caus ing  lysis o f  mouse  eryth-  
rocytes  in the presence  o f  WGA.  However ,  heat - t reated  
and  t ryps in i zed  vesicles were found to be inact ive.  No  
s igni f icant  leakage o f  hygromyc in  B was observed  dur -  
ing heat  t reatment ,  t ryps in i za t ion  or  dega lac tosy la t ion  
Table I 
Entrapment of hygromycin B in various virosomes and liposomes 
Virosomes Hygromycin B (,ug//~g F protein) 
F-virosomes 0.98 + 0.11 
F, HN-virosomes 1.00 + 0.14 
Heat-treated virosomes 0.97 -+ 0.11 
Fusogenic liposomes 10.32 + 1.04 
Hygromycin B was measured by its ability to inhibit polyphenylalan- 
ine synthesis in vitro. Virosomes containing hygromycin B were solu- 
bilized with Triton X-100 (0.1%, v/v). Aliquots from the solubilized 
extract were incubated with rabbit reticulocyte lysate in reaction 
buffer (10 mM Tris-HC1, 10 mM magnesium acetate, 100 mM NH4CI 
and 1 mM DTT, pH 7.8) supplemented with [~4C]phenylalanine and 
poly(U) for 1 h at 37°C. Radioactivity was then measured as described 
earlier [13]. The amount of hygromycin B entrapped in vesicles was 
then calculated from a standard curve plotted using free hygromycin 
B at known concentrations. Intact loaded vesicles failed to inhibit 
polyphenylalanine synthesis. 
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of virosomes. Moreover, leakage was found to be less 
than 5% after a 20 h incubation at 37°C. Intact loaded 
virosomes and liposomes were unable to inhibit pol- 
yphenylalanine synthesis. Moreover, Triton X-100 used 
for lysis also had no effect. Using ~25I-labelled viro- 
somes, it was found that heat-treated F-virosomes were 
able to bind to HepG2 cells to an extent similar to 
untreated F-virosomes. Degalactosylated F-virosomes, 
however, were unable to bind to the cultured cells due 
to the loss of  recognition by ASGP-R  owing to removal 
of  terminal galactose residues (data not shown). Thus, 
heat- treated F-virosomes were used as nonfusogenic 
targeted liposomes whereas degalactosylated F-viro- 
somes behaved as nontargeted fusogenic virosomes in 
this study. 
3.2. Interaction of various virosomes with HepG2 cells." 
fusion mediated microinjection of hygromycin B
The cytotoxic activity of  hygromycin B enclosed in 
F-, F, HN-  and F, HNr~d-virosomes was evaluated on 
HepG2 cell line and was assessed by measuring the 
inhibition of  DNA synthesis in these cells. Fig. 1 shows 
the dose response curve of  drug toxicity for HepG2 
cells incubated for 18 h with varying amounts of  loaded 
F-virosomes (Fig. 1A) or with F, HN-  and F, HNr~ d- 
virosomes (Fig. 1B). The drug encapsulated in all these 
virosomes was highly toxic and the toxicity increased 
with the increasing amount of  virosomes incubated with 
the cells. The drug encapsulated in F, HN-virosomes 
displayed higher toxicity (IDs0 = 0.001 pg) as compared 
to F- or F, HNrea-virosomes (IDs0 = 0.01 pg). As is evi- 
dent from Fig. 1, the inhibition of  DNA synthesis oc- 
curred only as a result of  introduction of  hygromycin 
B to the cells through loaded virosomes. Addit ion of  
free hygromycin B either alone or mixed with empty 
virosomes displayed low cytotoxic activity, i.e. about 
25-35% (Fig. 1A and B). 
Kinetic studies revealed that inhibition of  DNA syn- 
thesis in cells was progressive and 50% inhibition was 
achieved after 6 h of  incubation with loaded F- and 
F, HNrea-virosomes (Fig. 2A and B). However, the ki- 
netics of  inhibition was comparatively much faster with 
F, HN-virosomes, i.e. 50% inhibition was obtained 
within an hour (Fig. 2B). After long incubation with all 
these virosomes (18 h), most of  the cells in the culture 
were not viable. However, empty virosomes exhibited 
very low cytotoxicity as shown in Fig. 1. Loaded heat- 
treated F-virosomes and F, HN-virosomes behaved as 
targeted nonfusogenic proteoliposomes and were mildly 
toxic with only 30-35% inhibitory activity observed 
even after 18 h of  incubation. Free drug and drug mixed 
with blank virosomes responded similarly as that of  
heat-treated virosomes (Fig. 2A). Trypsinized viro- 
somes showed similar inhibition profile. This supported 
the view that introduction of  hygromycin B via loaded 
virosomes into cultured cells was mediated by a virus 
cell fusion process and that an active fusion protein is 
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Fig. 1. Dose-response curve of cytotoxic activity of free or encapsu- 
lated hygromycin B measured by DNA synthesis nhibition assay. 
HepG2 cells (2 x 105) were placed in culture plates for 24 h at 37°C 
in 5% CO2 followed by washing with culture medium. Cells were then 
incubated in 2 ml culture medium for 18 h at 37°C with various 
amounts of (A) free drug (closed triangles), free drug and empty 
F-virosomes (open triangles) or drug encapsulated in F-virosomes 
(closed circles) (B) free drug and empty F, HN-virosomes (open trian- 
gles), free drug and empty F, HNred-virosomes (open squares), drug 
encapsulated in F, HN-virosomes (closed circles) or F, HNroa-viro- 
somes (closed triangles). Amount of virosomes i expressed in terms 
of F protein associated with virosomes. The corresponding amount of 
free drug was taken as described in Table I. After incubation and 
washing with D-PBS, 0.2 /.tCi of [3H]thymidine was added in 1 ml 
culture media nd DNA synthesis was followed for 6 h. Cells were then 
fixed and radioactivity measured as described earlier [14]. Results are 
expressed as percent of DNA synthesis activity of cells incubated 
without free or enclosed rug. Each point is average of two independ- 
ent experiments. 
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Fig. 2. Inhibition of DNA synthesis in HepG2 cells by free or encap- 
sulated hygromycin B: kinetic study. HepG2 cells (2 × 105) were placed 
in culture plates for 24 h at 37°C. Cells were then incubated for various 
time periods at 37°C with 5 fig of (A) free drug (closed triangles), 
loaded heat treated F-virosomes (open triangles) or loaded F-viro- 
somes (closed circles) (B) loaded heat-treated F, HN-virosomes (open 
triangles), loaded F, HNred-virosomes (closed triangles) or loaded 
F, HN-virosomes (closed circles). Ceils were then washed with D-PBS 
and incubated with [3H]thymidine for 6 h. Radioactivity associated 
with cells was then measured as described in Fig. 1. Trypsinized viro- 
somes showed similar behaviour as that of free drug. 
required for this process. To prove that F-virosomes 
interact specifically with HepG2 cells, F protein in 
loaded F-virosomes was degalactosylated with clam ex- 
oglycosidase. Fig. 3 clearly indicates that nontargeted 
fusogenic F-virosomes were ineffective in causing inhi- 
bition of DNA synthesis and thus binding and fusion 
of virosomes with HepG2 cells is solely mediated by F 
protein leading to microinjection of hygromycin B. 
3.3. Fusion mediated microinjection of hygromycin B
with fusogenic liposomes containing Sendai viral F 
protein 
A comparative study of the toxicity of the drug en- 
trapped both in fusogenic liposomes and F-virosomes 
was carried out. Fig. 4 shows about a 3~-fold enhance- 
ment in the drug toxicity when it was enclosed in the 
fusogenic liposomes. This effect may be due to a combi- 
nation of the high trapping efficiency of liposomes and 
the fusogenic property of viral F protein. Heat-treated 
fusogenic liposomes exhibited significantly lower cyto- 
toxicity, indicating again that microinjection of hygro- 
mycin B is due to F protein mediated fusion process 
with HepG2 cells. The presence or absence of 10% fetal 
bovine serum in the medium during incubation of cells 
and virosomes/fusogenic liposomes did not exhibit any 
significant effect on the toxicity of the drug. 
4. DISCUSSION 
The results presented in this work clearly demon- 
strate the efficiency of reconstituted Sendai viral enve- 
lopes lacking hemagglutinin-neuraminidase in intro- 
ducing their contents into cultured cells. Hygromycin B
was entrapped in F-virosomes to study its targeted cy- 
tosolic delivery in HepG2 cells. Hygromycin B is a 
membrane impermeant broad spectrum antibiotic, able 
to kill cells by blocking the translocation ofphenylalan- 
ine tRNA and subsequently inhibiting protein and 
DNA synthesis only in cell-free systems or in the pres- 
ence of an ionophore [15]. We used a DNA synthesis 
inhibition assay as an index of cytotoxic activity of 
hygromycin B. A human hepatoma cell line, HepG2, 
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Fig. 3. Specificity of interaction of F protein with HepG2 cells. Cells 
(2 x 105) were grown for 24 h at 37°C and incubated for 18 h at 37°C 
with 10,ug of hygromycin B containing, F-virosomes (A), heat treated 
F-virosomes (B) or degalactosylated F-virosomes (C). DNA synthesis 
was then measured as in Fig. 1. 
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Fig. 4. Comparison ofthe toxicities of drug encapsulated in F-viro- 
somes and fusogenic liposomes for HepG2 cells. Cells (2 x 105) were 
placed in culture plates 24 h before assaying and further incubated for 
12 h at 37°C with hygromycin B containing: F-virosomes (cross- 
hatched), heat-treated F-virosomes (solid), fusogenic liposomes 
(blank), or heat-treated fusogenic l posomes (left-hatched). The x-axis 
represents the amount of F protein associated with virosomes and 
liposomes. Cytotoxicity was then measured asin Fig. 1. 
having a large number of functional asialoglycoprotein 
receptors on the cell surface [16] is known to bind and 
fuse with F-virosomes [4]. This specific interaction was 
further confirmed by the finding that the hygromycin B
entrapped in degalactosylated F-virosomes exhibited 
negligible cytotoxicity. Incubation of loaded F-viro- 
somes with HepG2 cells led to a strong inhibition of 
DNA synthesis indicating that the trapped drug was 
transferred to these cells by the fusion of F-virosomes 
with the recipient cell membranes. Support for the view 
that introduction of the antibiotic indeed occurred by 
F protein mediated fusion was obtained from the exper- 
iments showing that loaded nonfusogenic virosomes 
(heat-treated or trypsinized virosomes) caused very little 
inhibition of DNA synthesis in the cells. Heat treatment 
of virosomes i  known to abolish the fusogenicity of the 
F protein [10] without altering its galactose mediated 
binding to the ASGP-R of HepG2 cells [4]. Hence, the 
reduction of cytotoxicity of the heat-treated virosomes 
may be explained by their receptor mediated endocy- 
totic uptake and the probable degradation of the amin- 
oglycoside structure of the drug by lysosomal hydro- 
lases. 
A great deal of work has also been reported to gener- 
ate specificity on Sendai viral envelopes for fusion-me- 
diated microinjection of several biologically active mol- 
ecules to appropriate target cells in vitro [1]. The fusion 
of these engineered viral envelopes depends to a large 
extent on the presence and involvement of HN protein 
in addition to the specific attachment molecules. We 
report here for the first time the dual role (in binding 
and fusion) of F protein in fusion mediated elivery of 
hygromycin B to HepG2 cells. We have compared the 
cytotoxicity of hygromycin B loaded in F-, F, HN- and 
F, HNre~-virosomes. F, HNred-virosomes have been 
shown earlier to exhibit a slightly faster rate of lysis of 
RBC than that of F-virosomes only in presence of wheat 
germ agglutinin [4]. Reduced HN spans the virosomal 
membrane but is unable to bind to the sialic acid moiety 
of target cells [4]. Both dose dependence and kinetics of 
cytotoxic pattern of F- and F, HNrcd-virosomes were 
found to be quite similar confirming our earlier studies 
on hemolysis. On the other hand, F, HN-virosomes 
showed 10-fold more activity than F- and F, HNred-viro- 
somes as far as the IDs0 values were concerned. Moreo- 
ver, the kinetic studies revealed that F, HN-virosomes 
were about 1.5-fold more active than that of F- and 
F, HNred-virosomes in the initial (until about 6 h) phase 
of interaction with target cells. The enhancement of the 
cytotoxicity of F, HN-virosomes can be explained on the 
basis of attachment contributed by both F and HN 
protein to their respective receptors on the membrane 
of HepG2 cells, as reported earlier using a fluorescence 
probe-based membrane fusion assay [4]. Transmem- 
brane disposition of inactive HN protein (HNr~d) did 
not exhibit any significant contribution to the cytotox- 
icity of virosomes. It is important to note here that the 
final extent of inhibition caused by all these virosomes 
were about the same. The contribution of and absolute 
requirement for HN protein in the fusion process, de- 
scribed by Gitman et al. with erythrocytes [17] and 
hepatoma tissue culture cells [18] was not prominent in 
our experiments with HepG2 cells. We also observed a
3-4-fold enhancement of cytotoxicity of fusogenic li- 
posomes as compared to that of F-virosomes. This may 
be explained by the-10-fold more drug entrapped in 
liposomes with same F protein content. The efficacy of 
this targeted fusion mediated microinjection process 
can be expressed as amplification factor (AF) which can 
be be defined as the ratio of the free drug concentration 
to that of the targeted rug, measured at the same cyto- 
toxicity. The AF calculated in our virosomal systems 
are more than 10 4. Fusogenic liposomes containing Sen- 
dai viral envelope proteins have been recently used to 
target his antibiotic to leukemic T cells in vitro [19]. In 
this study, a specific monoclonal antibody against ar- 
get cell plasma membrane antigen has been employed 
to mediate functional binding between fusogenic vesi- 
cles and target cell membrane. Using these fusogenic 
immunoliposomes, AF values ranging from 102 103 
have been reported. 
The terminal sugar residues of the F protein may 
offer suitable sites to generate further specificity against 
various cell surface antigens and receptors. 'Trojan 
horse' strategies involving virosomes and fusogenic li- 
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posomes  in the field o f  gene therapy and drug del ivery 
are a l ready in the l imel ight o f  modern  b io techno logy  
[20]. We are current ly  engaged in eva luat ing the poten-  
tial o f  F -v i rosomes  and fusogenic vesicles as targeted 
bio logical  carr iers in vivo. 
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